Abivax in Paris (France) has released its phase IIa clinical results for an antiviral therapy for patients with HIV infection, which could potentially take a corner in an annual $18Bn market.
HIV and AIDs have a long-standing history (the quick – yet fascinating story of which can be read here), and since 1983 (when the HIV virus was identified to be responsible for this mystery disease) the WHO estimates 25 million to have died from its grasp.
ABX464 is a first-in-class orally available antiviral drug candidate for the treatment of patients with HIV infection. It blocks HIV replication through a unique mechanism of action that leads to the destruction of viral RNA. Abivax’s RNA Splicing platform has been developed in partnership with the French National Centre for Scientific Research (CNRS) in Montpellier, and the Institut Curie in Paris.
Abivax is also the first company to have established “a fruitful collaboration” with the Cuban Centre for Genetic Engineering and Biotechnology (CGIB) in Havana,